期刊
DIABETES CARE
卷 34, 期 11, 页码 2403-2405出版社
AMER DIABETES ASSOC
DOI: 10.2337/dc11-1248
关键词
-
资金
- Medtronic
- Abbott Diabetes Care
- Amylin
- Bayer
- Calibra
- Eli Lilly
- Intarcia
- Mann Kind
- Medtronic MiniMed, Inc.
- Novo Nordisk
- Pfizer
- ResMed
- Roche
- sanofi-aventis
- Blodel
- Hygieia
- Intuity
- Life Scan
- United Health Group
- Valeritas
- Biodel
- GlaxoSmithKline
- Becton Dickinson
- Hoffmann La Roche
- GlycoMark
- Wyeth
- Daiichi Sankyo
- Bristol-Myers Squibb
- Bayhill Therapeutics
- LipoScience
- MannKind
- MicroIslet
- Exsulin
- GI Dynamics
- Lilly
- Novartis
- Tolerex
- Osiris
- Halozyme
- Interkrin
- Merck
- Dexcom
- Johnson Johnson
- Fujisawa
- Boehringer Ingelheim
OBJECTIVE-To examine the effects of crossing over from optimized multiple daily injection (MDI) therapy to sensor-augmented pump (SAP) therapy for 6 months, and the effects of 18 months' sustained use of SAP. RESEARCH DESIGN AND METHODS-The 6-month, single-crossover continuation phase of Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) provided SAP therapy to 420 subjects who completed the 1-year randomized study. The primary outcome was change in A1C in the crossover group. RESULTS-A1C values were initially lower in the continuing-SAP group than in the crossover group (7.4 vs. 8.0%, P < 0.001). A1C values remained reduced in the SAP group. After 3 months on the SAP system, A1C decreased to 7.6% in the crossover group (P < 0.001); this was a significant and sustained decrease among both adults and children (P < 0.05). CONCLUSIONS-Switching from optimized MDI to SAP therapy allowed for rapid and safe A1C reductions. Glycemic benefits of SAP therapy persist for at least 18 months.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据